# PVL update — round 2 follow-up (v2, post-comments)

**For Claude Chat humanization** before sending to Peleg.

**Said's voice — preserve in humanization**:
- Direct, scientific peer-to-peer.
- Owns framing errors without over-apologizing.
- Gives the *reasoning* behind every recommendation, not just the recommendation.
- Asks only what we genuinely need from her. No fluff questions.
- Hebrew opening + closing per the v1 style.

**Length target after humanization**: 2200-2700 words.

**Don't include in the humanized email**:
- Slide-numbering reconciliation table (just use her slide numbers directly).
- Comment numbers (just talk about the content).
- Internal task IDs.

---

## Opening (paste as-is, then Claude Chat refines)

היי פלג,

Two things up front. First — apology: the document you reviewed was the question-bundle Claude Chat sent me before I finalized it; I accidentally forwarded it to you. Your 27 inline comments turned out to be more useful than the polished version would have been, so I'm not unhappy about it, but the slide numbering in that doc was off because the PDF I generated from your PowerPoint dropped three diagram-only slides during conversion (the FF-Helix / FF-SSW schematic illustrations on your slides 7, 12, and 13). Every "slide N" reference in the document I sent was off by 1 for some questions and by 3 for others. I'm using your actual slide numbers from this point on.

Second — you corrected my framing in three significant ways, and I want to lead with how we're updating because those corrections genuinely change what we ship. Then I'll go through the rest of your comments, then the questions I still need from you.

---

## §1 — Three places you re-framed our work, and how we're updating

### 1.1 — AMPs aren't false positives. They're correctly-flagged broader candidates.

I had been calling the AMP positives in the Staphylococcus validation "false positives." You corrected this in three layered comments (the ones on the FF-rule paragraph): the features that drive amyloid formation are the same features that allow membrane interactions — that's not noise, it's shared biophysics. And your lab's strategy of specifically testing AMPs and toxic peptides as fibril candidates was *because* of that shared feature space. So PSM-α2 showing up as FF-SSW positive is not a tool failure — it's the tool surfacing exactly the membrane-active-vs-amyloid distinction question your work investigates.

This rewrites how we describe FF-SSW in three places:
- The Help text and FF-SSW column tooltip will switch from "false positive class" language to "membrane-active overlap class with shared fibril-forming features."
- The validation brief (the internal document with the confusion matrix) reframes the 97% AMP-positive rate as "broader-scope candidacy, by design" rather than systematic error.
- The paper intro will use your framing — that AMPs and toxic peptides were initial targets because of the shared biophysics — as the scientific motivation for PVL's positive class definition.

I think this is the right framing and I'd rather get it correct now than have a reviewer flag it later. If you'd phrase any of this differently for the paper, tell me.

### 1.2 — "Everything that is SSW needs to be also of helix" was about symmetry, not subset.

I read your slide 1 line 5 ("everything that is SSW needs to be also of helix") as a strict subset axiom — that the 4-class Venn diagram should be redrawn with SSW *inside* Helix. Your clarification was clearer: you meant that any analysis or treatment we apply to SSW and FF-SSW should symmetrically apply to Helix and FF-Helix. The Venn stays as 4-sibling circles.

What I'm doing about it: a sweep across every classification surface in PVL to confirm we treat all four flags consistently. Where we don't, we'll fix. The Quick Analyze badge symmetry is one example you flagged already (the "No SSW" badge appeared without Helix / FF-Helix / FF-SSW counterparts) — that's fixed in the build I'm sending you now.

### 1.3 — The threshold citation is Ragonis-Bachar and Rayan, not Eisenberg.

You answered my Q4 directly: the threshold values should be cited as Ragonis-Bachar and Rayan, not Eisenberg 1984. I'll update the Help text, the threshold tooltip, and the paper methods the moment I have the DOI — see the questions section below.

### 1.4 — Helix and FF-Helix, full stop. The "%" is a feature, not a class.

You said: *"There should be only two terms: Helix and FF-Helix. The % should just be another feature indicating what percentage of the sequence was predicted to be helical and should be treated as a separate variable/parameter."*

Clear. The classes are **Helix** and **FF-Helix** (and **SSW** / **FF-SSW**). The percent value — what fraction of the sequence S4PRED predicts as helical — is a parameter we display alongside the class, not a third name. I'm sweeping the UI to:
- Drop "FF-Helix %" as a column / badge label. The column becomes "Helix %" (or "S4PRED helix content"), with the tooltip stating it's the percentage of residues predicted helical by S4PRED.
- Keep the FF-Helix class label intact — that's the candidate flag (helix + μH threshold).
- Update the Smart Candidate Ranking weight slider that was labelled "FF-Helix %" to the same "Helix %" feature name.

That removes the "is FF-Helix a class or a percent?" ambiguity in one pass.

---

## §2 — Your specific comments, addressed in order

A compressed pass through the rest of your comments. Where the action is "we already did this" I keep it brief; where it requires more discussion I expand.

### On validation framing (general comment at the top)

Agreed — n=66 labeled subset is too small for definitive scoring claims. The paper will frame the Staphylococcus analysis as exploratory: useful for surfacing the membrane-active overlap class, not for claiming a sensitivity number. Your two reasons (secondary-structure-switch under-researched in the literature; fibril formation is environmentally conditional, so "doesn't form fibril" is always provisional) will both go into the limitations section explicitly.

### On the 4-class redefinition (your slide 30)

You wrote "AND with that being said, it is perfectly fine that we report or call name for fibril dormation potential only, it is fine if other biological functionalities might also happen." Got it — FF-SSW name stays. The Help text will add a single sentence acknowledging that "fibril-forming potential" recognizes that some flagged peptides may have membrane-active as their primary biological function, without splitting the class or changing the flag.

### On automatic thresholds (your slide 30, the "more flexible / automatic" comment)

Confirmed — keeping automatic threshold derivation (cohort median in Recommended mode) as the default. I'll state this explicitly in the methods so the design intent is on the record. This is one of the things I think we should mention in the paper as a deliberate choice rather than an implementation detail.

### On the canary set (Aβ42 too long)

You're right, Aβ42 at 42 residues is past PVL's reasonable pipeline length. Two fixes:
1. I'm replacing Aβ42 in the canary test suite with Aβ16-22 (KLVFFAE) — the classic short amyloid-forming fragment that fits the pipeline range.
2. I'm adding an upfront length-warning in the pipeline: when a user uploads peptides longer than the recommended max, they'll see a warning before processing.

The thing I need from you is the actual length cap — I have a number in mind (40 aa, see questions below), but you have the experimental intuition here.

### On negative controls ("there is no real negative control in this field")

You're right and we shouldn't call them that. The Poly-GS and Poly-E entries in the suite aren't asserting non-fibrillation — they're regression canaries (detecting if our FF-Helix percentage calculation drifts in a future change). I'll rename them to "regression canaries" in the code and documentation. If you have a better term, tell me.

### On UniProt keyword annotations as data (not ranking)

Your comment: "Not sure about using the UniProt keywords as ranking (unless the user wants to) but definitely adding this information will be beneficial regardless of ranking." Done as you'd expect: UniProt keywords become a visible chip on each peptide row (researchers see "Antimicrobial / Defensin / Signal" alongside the FF-SSW flag). The keyword-downweighting in the candidate ranker stays opt-in — the user can toggle it on if they want to push AMPs down the list, but it's off by default.

### On the "different scoring rule" and "class-splitting" options I proposed

Both rejected, both for the right reasons:
- Multi-feature learned scoring rule — you said it's not feasible without much more labeled data. Agreed. Dropped.
- Splitting the positive class into "amphipathic switch candidate" and "amyloid switch candidate" — you pointed out that's already what PVL does (SSW broader, FF-SSW narrower with the hydrophobicity gate). I was proposing something we already have. Dropped.

### On omitting AGGRESCAN / PASTA / AmyloDeep from the disclosure

Your approval, plus the framing that's actually gold for the paper: "they will miss these sequences since they are basing their prediction on the propensity to form β-sheets, which is the opposite of what we are doing." That's the differentiator I should be leading with in the intro — competitors predict β-sheet propensity; PVL predicts the α-helix → β-sheet *switch*. I'm restructuring the paper intro around this framing.

### On the cohort → database wording

Your comment "Still not convinced we need to change the terminology. what is the problem with FF-a-helix and FF-SSW?" — I think there's a misunderstanding here that's my fault. The "database" wording in the disclosure paragraph was the cohort → database rename you asked for in your original PowerPoint feedback (your slide 15 in the PPT, where you wrote "I would use the name database instead of a cohort"). I am NOT proposing to rename the FF-α-helix or FF-SSW flags. They stay as is. The only thing that changed is "cohort mean" → "database mean" in the comparison text.

### On the AlphaFold framing

"Just in title, AlphaFold3 predicted 3d structure. In the paper we will emphasize this." Applying this two ways:
1. The card title in the UI is being renamed from "Sequence & Structure" to "AlphaFold-predicted structure" so the predicted-not-experimental nature is in the title, not buried in a footnote.
2. The paper methods will emphasize this prominently, with a note that we restrict structural-overlay interpretation to the high-confidence regions when relevant.

### On the reproducibility permalink

"This is SUPER COOL and indeed no other tool I know have this and we will emphasize this in the paper." Got it — I'll give it a dedicated paragraph in the methods. The figure pack inherits the same permalink in its methods panel, so a reader of the supplement can regenerate the exact figure by pasting the URL.

To answer your follow-up comment ("you mean a different paper??"): no, I meant a dedicated section in the main paper, not a separate publication. The reproducibility permalink is a differentiator that belongs in the main PVL paper, not its own.

### On "what does the % mean" (Smart Candidate Ranking)

There are two different "%"s in the same UI, which is the confusion you flagged:
- The **per-metric weight sliders** sum to 100% — that's how much each metric contributes to the final score.
- The **final ranking score** is also 0-100 — but that's the percentile-aggregated score across your selected peptides.

I'm renaming both to remove the ambiguity:
- The weight sliders will be labeled "Weight (out of 100)" with a tooltip explaining they sum to 100% across enabled metrics.
- The final score column will be labeled "Score (0-100)" with a tooltip explaining it's the percentile rank within your dataset, weighted across selected metrics.

Same fix for the FF-Helix % column you also flagged — the tooltip will read: "Percentage of residues that fall inside 6-residue sliding-window segments where the mean Fauchère-Pliska helix propensity exceeds 1.0. So FF-Helix = 60% means 60% of residues are part of helix-propensity-positive windows."

Same fix for TANGO aggregation max — the tooltip will read: "Peak per-residue TANGO aggregation propensity across the sequence. Highest point on the TANGO curve, scored 0-100."

### On the MCP server question

"So.. if I am understanding correctly this is something you already implemented?" — yes. The MCP server is shipped. It exposes PVL's analysis primitives (get_peptide_detail, rank_candidates, compare_cohorts, find_similar, analyse_sequence) so any AI assistant that speaks MCP (Claude Desktop, Cursor, Continue) can drive PVL from natural language. A researcher with PVL configured in their assistant can say "screen these 50 sequences for amyloid candidates" and the assistant orchestrates the calls. I'll demo this on the Zoom we're scheduling.

### On the PubMed/PMC RAG point

"Not sure I fully understood this point" — quick explanation: when an AI assistant answers a question about a peptide, RAG (Retrieval-Augmented Generation) has it fetch relevant papers from PubMed/PMC first and cite them in the response. So instead of "this peptide is amyloidogenic" with no source, it would say "amyloidogenic per Smith et al. 2024 (PMID 12345)" with a real citation. The hard problems are building the literature vector database and preventing hallucinated citations. This is Alex's longer-term vision and we have it queued, but it needs scientific co-design with you on what "good cite-grounded answers" look like — confidently mis-cited papers would be worse than no citation at all. We'll get to this after the MCP base proves itself and Maxwell access lands.

### On the SaaS / open-access discussion

Your confirmation matches our decision. We're staying open-access, no auth, no email gating — the journal requirement just reinforces what we'd already chosen.

### On the distribution of the tool

You wrote that what we already have is enough, and what we need is for young researchers searching for "amyloid" or "fibril" + "peptide" to find PVL easily. Two thoughts:

1. **On the name** — I'd rather brainstorm with you in the Zoom than ship a name I'm only 60% on. I have a starting shortlist (FibrilLens, AmyloPath, ChameleonPep, Helix2Sheet) that we can use as a jumping-off point, but the decision is yours and Alex's as much as mine.

2. **On discoverability post-rename** — once we have the name, I want to set up the GitHub repo + bio.tools registration + Zenodo DOI under it so an Msc student searching "amyloid peptide prediction" will land on us within the first few results. None of this is hard once we agree on the name.

---

## §3 — Code changes landing this week from your feedback

These are landing in the build at `http://94.130.178.182:3000` over the next few days. Refresh to see them progressively:

- "False positive" language stripped from the validation brief and Help text; replaced with "membrane-active overlap class" framing per your correction.
- Aβ42 replaced with Aβ16-22 (KLVFFAE) in the regression canary suite. Length-cap warning added to the upload flow.
- "Negative controls" → "regression canaries" in the code documentation.
- UniProt keyword chips on each peptide row.
- AlphaFold card title renamed to "AlphaFold-predicted structure."
- FF-Helix % / TANGO aggregation max / Smart Ranking labels and tooltips clarified per the section above.
- Symmetry sweep across all 4-class surfaces.
- Citation to Ragonis-Bachar and Rayan will replace any Eisenberg reference the moment I have the DOI.
- 40-aa pipeline cap encoded as the new default in `config.py`; upload + Quick Analyze warnings rewritten in your language (surface-vs-structure problem, not "reduced accuracy").
- **Cohort Comparison chart** (the one you annotated): the colour scheme is flipped per your direction — "No SSW" / "No Helix" now brown-orange, "SSW" / "Helix" green, "FF-SSW" / "FF-Helix" darker green. The feature-cluster spacing on the x-axis is also widened so the bars breathe. The chart is now rendered as **two parallel comparisons** (SSW grouping + Helix grouping side-by-side) so the symmetry-of-treatment principle from §1.2 is visible at a glance.
- **FF-Helix vs Aggregation Max scatter** (peptide detail page) now has both axis labels ("FF-Helix %" / "Peak TANGO aggregation score") and a visible legend (Current peptide / Database) under the chart.
- "FF-Helix %" rename audit: column header, tooltip, and Smart Ranking weight-slider label switching to "Helix %" so it's clear the percent is a feature, not a class name. Two terms only: Helix and FF-Helix, as you wrote.

If you want to verify any of these on the live URL once they land, the most diagnostic test peptide is still P0C005 (Anoplin) — the EvidencePanel on its detail page will show TANGO's actual verdict in its breakdown, with the unified SSW summary on top. That's the structural fix the FF-SSW question you raised on Slack led to.

---

## §4 — Questions I genuinely need from you

I trimmed this to four. Everything else either has an answer or can wait for the Zoom.

### Q1 — Pipeline length cap [ANSWERED, encoded]

Your follow-up: *"It should definitely be a hard cutoff (NOT only a warning), and the cutoff should be 40. In my code there was supposed to be a length cutoff at the first stages. The reason lies in the calculation itself. More than this, the secondary structure prediction becomes more complicated; we then need to look for surface and not only secondary structure, and it just misses the point."* Plus: *"40 it is! The user can define length limitation of his own, only if it between 10-40."*

Encoded already in the build I'm sending you. The 40-aa cap is now the default in `backend/config.py` (`PEPTIDE_LENGTH_HARD_MAX = 40`, with a user override clamped to the `[10, 40]` window — `PEPTIDE_LENGTH_USER_OVERRIDE_MIN/MAX`). The upload-screen warning and the Quick Analyze warning both now state explicitly that the secondary-structure prediction becomes a surface-vs-structure problem above 40 and those rows will be skipped, rather than the previous "reduced accuracy" language.

One thing I should flag honestly: I shipped the cap as the *default* in this build. Switching it to a *hard reject* at the upload route (so a sequence > 40 aa cannot be processed at all) is a behaviour change that touches the API contract and the batch-processing path, and I want to land it in its own focused PR rather than bundled with the cohort-chart and Help-text changes. That's queued as the next backend wave. If you need it as a hard reject before something specific (a demo, a deadline), tell me and I'll bump it forward.

### Q2 — Help-page section text (4 classes)

You wrote out exact language for the four Help-page sections (Alpha-helix secondary structure, Fibril-forming alpha helix, Secondary structure switch, Fibril-forming secondary structure switch). I want to ship those four sections verbatim from your text — preserving your phrasing on "indecisive prediction" and the μH / hydrophobicity gating — rather than paraphrase. Two minor questions before I paste-in:
1. Should the "secondary structure switch" definition reference both **maximum gap threshold** and **minimum % SS content** (two configurable thresholds you flagged earlier), or only the gap threshold?
2. For FF-SSW, you wrote "hydrophobicity is higher than the threshold hydrophobicity". Confirming we're keeping the hydrophobicity threshold (not the μH one) as the FF-SSW gate — yes?

### Q3 — Quick confirmation on the framing direction

A few one-line confirmations so I can ship without re-bothering you:
- **"Regression canaries"** as the new term for what we used to call negative controls — OK?
- **Including the Staphylococcus 2023 analysis in the paper as an exploratory section in the limitations**, not as a primary validation — OK?
- **Your framing on AMPs and toxic peptides as initial targets** (because of shared feature space with amyloid formers) — would you like this in the paper intro as the scientific motivation for PVL's positive class? My instinct is yes, but I want your sign-off because it's a positioning choice.
- **The α-helix → β-sheet switch as PVL's differentiator** vs. competing tools that predict β-sheet propensity directly (your framing in the omitting-competitors comment) — same question, paper intro, OK?

### Q4 — Your TANGO-aggregation-by-stretches code

You wrote: *"If we are referring to the aggregation of Tango, we should apply the same method we used to obtain the secondary structure prediction, only now passing the array of Tango aggregation scores to the functions… we need to find a long-enough stretch of residues that have a Tango aggregation score that is above 0 and average only their scores… It is fairly easy to implement this using the part of my code that finds secondary structure by sending the tango aggregation score list with average score limitation = 0 (meaning no average limitation). Let me know if you need help finding this in my code."*

Yes, I need help finding it. Could you point me at the function name (or paste the relevant snippet) of the SSW-fragment finder you'd reuse here? Once I have the reference, I'll thread the TANGO per-residue score array through the same algorithm with `avg_limit=0` and replace both the current "average all" and "max only" paths with one stretch-aggregated TANGO value per peptide. The existing "max" can stay as a secondary display, but the primary aggregation score the UI shows will be the stretch-averaged one you described.

### Q5 — Black "G" residue colouring

You wrote: *"It should be derived from the calculations. Otherwise, we are not showing the results of the pipeline. It should be taken from the column named: Helix fragments (S4PRED) / SSW fragments (Tango) / SSW fragments (S4PRED). My algorithm takes into account and smooths these small gaps (under 3, hence this threshold)."*

Got it — the residue colour comes from your fragment-column output, not from the per-residue S4PRED probability we were reading. To implement: I want to read the three fragment columns directly from the pipeline output and colour every residue inside any fragment, including residues inside a gap ≤ 3 between two fragments. Two confirmations before I touch the renderer:
1. The gap-smoothing rule (gap < 3 → merge fragments → colour the gap too) should apply to all three fragment families (Helix-S4PRED, SSW-TANGO, SSW-S4PRED) in the same way — yes?
2. When the three fragments disagree on a residue (S4PRED says "helix fragment", TANGO says "SSW fragment"), the renderer picks the more-specific class (Helix over SSW, or vice-versa)? I'll default to "show both with one priority colour" unless you'd prefer one wins outright.

### Q6 — Ragonis-Bachar and Rayan paper citation

For the threshold defaults — could you send the DOI or full citation of the Ragonis-Bachar and Rayan paper that defines the threshold values? I want to put the citation in the Help text + threshold tooltip + paper methods immediately so the source is on the record. If there are multiple relevant papers, I'll cite the most appropriate.

### Q7 — Zoom for D1-D5 + rename brainstorm

I'd like to schedule about 60 minutes to work through D1-D5 (the co-design items: Interpretation Notes decision tree, 4-class labeling and ordering, Tier 1 certainty derivation, Smart Ranking presets, SSW Score in ranking) together with the rename brainstorm. Alex is welcome on the call but it's not strictly required.

What slot works in the next 2 weeks?

---

## §5 — Live URL for verification

`http://94.130.178.182:3000` — hard refresh once the §3 items land (I'll send a quick note when each batch deploys). The diagnostic peptide P0C005 (Anoplin) is still the cleanest test of whether the SSW/FF-SSW story is rendering honestly.

If you'd rather do a screen-share than verify async, that can be part of the Zoom too.

---

תודה ממש, פלג. הקובץ ששלחת באמת באמת עזר, ועם 27 הערות מפורטות כאלה אנחנו ממש מתקרבים למוצר שהוא ראוי לפרסום. אני זמין מתי שתרצי.

— Said
